Edmond DE Rothschild Holding S.A. Boosts Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Edmond DE Rothschild Holding S.A. boosted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 36.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 563,530 shares of the biotechnology company's stock after acquiring an additional 150,303 shares during the quarter. Edmond DE Rothschild Holding S.A. owned 0.30% of BioMarin Pharmaceutical worth $37,041,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. FMR LLC boosted its position in shares of BioMarin Pharmaceutical by 21.7% during the third quarter. FMR LLC now owns 206,538 shares of the biotechnology company's stock valued at $14,518,000 after buying an additional 36,877 shares during the last quarter. Quantbot Technologies LP bought a new stake in BioMarin Pharmaceutical in the 3rd quarter worth about $171,000. Glenmede Trust Co. NA bought a new stake in BioMarin Pharmaceutical during the third quarter worth $254,000. Rockefeller Capital Management L.P. boosted its holdings in shares of BioMarin Pharmaceutical by 16.5% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 266,633 shares of the biotechnology company's stock worth $18,742,000 after buying an additional 37,805 shares during the last quarter. Finally, Captrust Financial Advisors grew its position in BioMarin Pharmaceutical by 34.1% during the third quarter. Captrust Financial Advisors now owns 10,900 shares of the biotechnology company's stock valued at $766,000 after buying an additional 2,770 shares during the period. Institutional investors and hedge funds own 98.71% of the company's stock.

BioMarin Pharmaceutical Trading Up 0.6 %

Shares of NASDAQ BMRN traded up $0.38 during mid-day trading on Wednesday, hitting $68.32. The stock had a trading volume of 1,448,619 shares, compared to its average volume of 1,843,927. The firm has a market cap of $13.03 billion, a P/E ratio of 31.05, a price-to-earnings-growth ratio of 0.61 and a beta of 0.33. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33. The business has a 50 day moving average price of $67.75 and a two-hundred day moving average price of $67.30. BioMarin Pharmaceutical Inc. has a 1 year low of $60.63 and a 1 year high of $94.85.

Remove Ads

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, beating analysts' consensus estimates of $0.54 by $0.18. The company had revenue of $747.31 million during the quarter, compared to the consensus estimate of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. On average, equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BMRN has been the subject of several recent research reports. StockNews.com lowered BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Tuesday. Royal Bank of Canada reiterated a "sector perform" rating and issued a $70.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Bank of America upped their price target on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Wedbush reaffirmed an "outperform" rating and issued a $94.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Finally, Oppenheimer raised shares of BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 target price on the stock in a report on Monday, February 24th. Seven analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, BioMarin Pharmaceutical has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,295 shares of the stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.52, for a total value of $92,618.40. Following the completion of the transaction, the chief accounting officer now owns 16,955 shares in the company, valued at approximately $1,212,621.60. This represents a 7.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.85% of the stock is owned by insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.